5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical features of germ cell tumors (GCT) in men age 50 or older: Successful outcome and tolerability to chemotherapy for advanced disease
    Meeting Abstract

    Voss, M. H.; Jacobsen, E. P.; Patil, S.; Turkula, S.; Jia, X.; Sheinfeld, J.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J.; Feldman, D. R.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Molecular classification of sunitinib response in metastatic renal cell carcinoma (mRCC) patients by gene expression profiling
    Meeting Abstract

    Thodima, V. J.; Molina, A. M.; Jia, X.; Zhang, J.; Georges, M. E.; Patil, S.; Reuter, V. E.; Motzer, R. J.; Chaganti, R. S.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Prevalence of prostate cancer (PC) clinical states (CS) in the United States: Estimates using a dynamic progression model
    Meeting Abstract

    Solo, K.; Mehra, M.; Dhawan, R.; Valant, J.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): A dynamic tumor model of the RECORD-1 phase III trial
    Meeting Abstract

    Stein, A. M.; Carter, A.; Hollaender, N.; Motzer, R. J.; Sarr, C.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A six-gene panel that predicts survival in men with castration-resistant prostate cancer
    Meeting Abstract

    Subudhi, S. K.; Heller, G.; Anand, A.; Danila, D. C.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase I dose-escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in patients (pts) with castration-resistant prostate cancer (CRPC): Final results
    Meeting Abstract

    Slovin, S. F.; Morris, S.; Kargman, M.; Durso, R.; Curley, T.; Israel, R. J.; Olson, W. C.; Murphy, D.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial
    Meeting Abstract

    Rini, B. I.; Escudier, B.; Tomczak, P.; Kaprin, A.; Hutson, T. E.; Szczylik, C.; Tarazi, J. C.; Rosbrook, B.; Kim, S.; Motzer, R. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Saad, F.; Akaza, H.; Eisenberger, M. A.; Nelson, J.; Scher, H. I.; Suzuki, K.; Wirth, M.; Webb, I. J.; Wang, J.; MacLean, D.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save